ABEONA THERAPEUTICS INC. 8-K

What Happened
Abeona Therapeutics Inc. announced that on April 1, 2026 its Board expanded from nine to ten members and appointed Keith A. Goldan as a Class 1 director, with a term expiring at the company’s 2026 annual meeting of stockholders. The Board also named Mr. Goldan Chair of the Audit Committee and determined he is an independent director under Nasdaq rules. The company filed a press release about the appointment on April 7, 2026 (Exhibit 99.1).

Key Details

• Board expanded from 9 to 10 members; Keith A. Goldan appointed April 1, 2026.
• Mr. Goldan will serve until the 2026 annual meeting (Class 1 director).
• Compensation: $50,000 annual cash board fee plus a one-time $150,000 sign‑on equity grant in restricted stock (one‑year vesting). Eligible for regular equity grant in 2027.
• Company reported no family relationships, related-party transactions, or special arrangements related to the appointment.

Why It Matters
A new independent audit committee chair can influence financial oversight and governance, which investors monitor for controls, reporting quality, and risk oversight. The appointment increases the Board size and updates committee leadership without any disclosed related-party issues. The cash and equity compensation terms are standard director pay and may modestly increase non-employee director expense going forward.